Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Eculizumab (Soliris) in Atypical Hemolytic Uremic Syndrome
2025-000162-29Phase 3
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Number of Participants Considered as Complete Thrombotic Microangiopathy (TMA) Responders.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2025-000162-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000162-29.